REOPRO (Janssen Biotech, Inc.)
Welcome to the PulseAid listing for the REOPRO drug offered from Janssen Biotech, Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Janssen Biotech, Inc. |
| NON-PROPRIETARY NAME: | abciximab |
| SUBSTANCE NAME: | ABCIXIMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2017-01-03 |
| END MARKETING DATE: | 0000-00-00 |
REOPRO HUMAN PRESCRIPTION DRUG Details:
| Item Description | REOPRO from Janssen Biotech, Inc. |
| LABELER NAME: | Janssen Biotech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 2(mg/mL) |
| START MARKETING DATE: | 2017-01-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 57894-200_3e79eaa7-651f-4878-a2c7-e575f1cac040 |
| PRODUCT NDC: | 57894-200 |
| APPLICATION NUMBER: | BLA103575 |
Other ABCIXIMAB Pharmaceutical Manufacturers / Labelers:
